CMS Updates ESA Coverage Policy for Cancer Patients (NCD 322): What Billing Teams Need to Know
The Centers for Medicare & Medicaid Services (CMS) has issued a modification to National Coverage Determination (NCD) 322, governing erythropoiesis stimulating agent (ESA) coverage for Medicare beneficiaries with cancer and related neoplastic conditions, effective March 12, 2026. This policy directly affects how oncology and hematology practices document medical necessity, initiate ESA therapy, and manage dose adjustments under Medicare. If your billing team isn't current on the hemoglobin thresholds and non-covered indications outlined here, you're looking at claim denials and potential compliance exposure.
| Field | Detail |
|---|---|
| Payer | Centers for Medicare & Medicaid Services (CMS) |
| Policy | Erythropoiesis Stimulating Agents (ESAs) in Cancer and Related Neoplastic Conditions |
| Policy Code | NCD 322 |
| Change Type | Modified |
| Effective Date | 2026-03-12 |
| Impact Level | High |
| Specialties Affected | Oncology, Hematology, Hematology-Oncology, Infusion Centers, Hospital Outpatient |
| Key Action | Audit current ESA orders against the updated hemoglobin initiation and maintenance thresholds before the March 12 effective date. |
What CMS NCD 322 Covers — and What It Doesn't
CMS covers ESA treatment for anemia secondary to myelosuppressive anticancer chemotherapy, but only within tightly defined parameters. The policy applies to solid tumors, multiple myeloma, lymphoma, and lymphocytic leukemia. Outside of those diagnoses, coverage is far more restricted.
ESAs are FDA-approved to reduce the need for blood transfusions in specific clinical settings, and CMS aligns its coverage with those FDA indications. However, the FDA has issued warnings about serious and life-threatening events associated with oncologic ESA use — and this policy reflects that caution through its strict medical necessity criteria and a detailed list of nationally non-covered indications.
Understanding where coverage ends is just as important as knowing where it begins. Billing an ESA for a non-covered indication isn't just a denial risk — it's a medical necessity problem that can trigger audits.
CMS ESA Medical Necessity Criteria: The Hemoglobin Rules
This is where most billing errors happen. CMS has established specific hemoglobin (Hgb) and hematocrit (Hct) thresholds that must be met and documented at every stage of treatment — initiation, maintenance, dose escalation, and dose reduction.
To initiate ESA therapy, the hemoglobin level immediately prior to starting treatment must be < 10 g/dL (or hematocrit < 30%). This threshold applies to both new starts and reinitiation after a treatment gap. There is no coverage for prophylactic use — the anemia must already be present.
Starting dose limits are set by FDA label:
| # | Covered Indication |
|---|---|
| 1 | Epoetin: no more than 150 U/kg, three times weekly |
| 2 | Darbepoetin alfa: no more than 2.25 mcg/kg, once weekly |
| 3 | Equivalent doses over other FDA-approved time periods are acceptable |
For maintenance therapy, the starting dose continues if, at four weeks, the hemoglobin remains below 10 g/dL and the rise is ≥ 1 g/dL (hematocrit ≥ 3%). Both conditions must be met — not just one.
If the four-week response is inadequate (hemoglobin rise < 1 g/dL or hematocrit rise < 3%), the FDA label starting dose may be increased once by 25%. However, if hemoglobin still hasn't risen by ≥ 1 g/dL after eight weeks of treatment, continued use is not reasonable and necessary — meaning continued claims will not be covered.
If hemoglobin rises too quickly — more than 1 g/dL over two weeks — continued administration is not reasonable and necessary unless the hemoglobin remains below or falls back to < 10 g/dL. When therapy is continued or reinstituted after a rapid rise, the dose must be reduced by 25% from the previously administered dose.
Treatment duration includes the eight weeks following the final dose of myelosuppressive chemotherapy in a given regimen. This window is often missed — ESA claims submitted after this period will not meet medical necessity under this NCD.
CMS Non-Covered ESA Indications Under NCD 322
CMS has nationally non-covered the following ESA uses in cancer patients. Billing for any of these will result in denial:
| Non-Covered Indication | Clinical Rationale |
|---|---|
| Anemia due to folate deficiency, B-12 deficiency, iron deficiency, hemolysis, bleeding, or bone marrow fibrosis | Cause is not myelosuppressive chemotherapy |
| Anemia associated with CML, AML, or erythroid cancers | ESA may have deleterious effect on underlying disease |
| Anemia of cancer not related to cancer treatment | ESA use increases risk of adverse effects |
| Anemia associated only with radiotherapy | No covered indication |
| Prophylactic use to prevent chemotherapy-induced anemia | Anemia must be present at initiation |
| Prophylactic use to reduce tumor hypoxia | Not a covered clinical rationale |
| Erythropoietin-type resistance due to neutralizing antibodies | Drug is not clinically effective |
| Anemia from cancer treatment with uncontrolled hypertension | Safety contraindication |
For practices treating patients with mixed diagnoses or overlapping conditions, clear documentation distinguishing the cause of anemia is essential for every claim.
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
Affected Codes
This policy document does not list specific CPT or HCPCS codes. CMS's NCD 322 is a coverage determination that governs ESA drug administration broadly under the Drugs and Biologicals benefit category. For HCPCS J-codes applicable to specific ESA products (such as epoetin alfa or darbepoetin alfa), reference your Local Medicare Administrative Contractor (MAC) LCD and billing guidelines, which operate within the parameters set by this NCD.
CMS notes that Local Medicare Administrative Contractors may continue to make reasonable and necessary determinations on ESA uses not specified in this national determination — meaning MAC-level policy still applies for indications not explicitly addressed here.
What Your Billing Team Should Do
| # | Action Item |
|---|---|
| 1 | Audit open and upcoming ESA orders against the updated Hgb/Hct thresholds before March 12, 2026. Pull a report of active ESA patients in your oncology or infusion practice and confirm that documented hemoglobin values at initiation and each maintenance check are below 10 g/dL (or hematocrit < 30%). Any patient whose labs don't support those thresholds needs a clinical review before the next administration. |
| 2 | Update your clinical documentation templates to capture all CMS-required data points. Your records need to show the hemoglobin level immediately prior to each ESA administration, the dose administered, the week of therapy, and whether a dose adjustment was made — including the reason. A generic lab result in the chart is not sufficient if it isn't explicitly tied to the ESA order. |
| 3 | Train ordering providers on the rapid-rise rule and the 25% dose reduction requirement. When hemoglobin rises more than 1 g/dL over any two-week period, continued administration without a dose reduction violates the policy's reasonable and necessary standard. This is a high-frequency audit target. |
| 4 | Flag patients with non-covered indications before drug administration, not after. Work with your oncology nurses and care coordinators to screen for the eight nationally non-covered indications — particularly uncontrolled hypertension, iron deficiency anemia, and CML/AML diagnoses — before ESA orders are placed. |
| 5 | Confirm the eight-week post-chemotherapy window on all ESA claims. Set a systematic end-date trigger in your billing system tied to the final chemotherapy dose in each regimen. Claims submitted beyond the eight-week post-treatment window will not meet medical necessity under NCD 322. |
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.